3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Squamous Cell Carcinoma of Head and Neck
3
Melanoma
3
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Solid Tumors, Adult
1
Lung Neoplasms
1
Lung Diseases
1
Colorectal Neoplasms
1
Carcinoma
1
Bronchial Neoplasms
1
Breast Neoplasms
1
Interventions
pembrolizumab
7
Ipilimumab
7
Nivolumab
5
Melphalan
5
Dacarbazine
3
tebentafusp
2
sotrastaurin
2
binimetinib
2
Pemetrexed
2
Crizotinib
2
ADI PEG20
2
utomilumab
1
trametinib
1
tocilizumab
1
siremadlin
1
ruxolitinib
1
relatlimab
1
obinutuzumab
1
fludarabine phosphate
1
fludarabine
1
cemiplimab
1
avelumab
1
Watchful Waiting
1
Toll-Like Receptor 1
1
Standard of Care
1
Solutions
1
Rose Bengal
1
Protein Kinase C
1
Polyethylene Glycols
1
Opdualag
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Uveal Melanoma
×
Toll-Like Receptor 1
×
Clear all
NCT05576077
2025-03-10
STARLING
Turnstone Biologics, Corp.
Phase 1
Terminated
31 enrolled